NewInsight: Anthropic's IPO price against 48 tech IPOs since 1997

Braveheart Bio BRVE

Braveheart Bio listed on Nasdaq on 6 Aug 2026 and is not in the S&P 500. It is worth $1.7 billion. Its price history starts on 7 Aug 2026. 9 directors have filed with the SEC in the last 12 months (who counts), 1 of them an executive. 2 other officers are on file.

CEO
Travis Murdoch
Listed
6 Aug 2026 on Nasdaq, IPO filings and terms
Headquarters
San Francisco, CA
Market cap
$1.7B
19 Nov 2026 close
Revenue
-
No annual report yet

Financials

Braveheart Bio's market cap since August 2026

Weekly, up to 13 Nov 2026

Sep 2026OctNov$1.8B

Board and leadership

Board and officers

1 person here also holds roles at other S&P 500 companies.

Roles filed up to 30 Sep 2026

NameTitle
Directors (9)
Travis MurdochCEO and PresidentCEO and President
Vineeta AgarwalaDirectorDirector
Jasper BosDirectorDirector
Erez ChimovitsDirectorDirector
Jason V. ColomaDirectorDirector
Tim LohoffDirectorDirector
David Charles LubnerDirectorDirector
David I. MalekDirectorDirector
Christopher ViehbacherDirectorAlso at BiogenDirector
Officers (2)
James Paul RickeyChief Financial OfficerLast filed 7 Aug 2026Chief Financial Officer
Michele A. AndersonChief Development OfficerLast filed 7 Aug 2026Chief Development Officer

Owners and trading

Insider trades

Open-market buys and sales by directors and officers. Grants, option exercises and shares withheld for tax are left out.

Trades from 19 Nov 2025 to 19 Nov 2026

Directors and officers made no open-market sales and bought $39.5 million in 7 purchases in the 12 months to 19 Nov 2026.

DatePersonTitleTypeSharesValue
7 Aug 2026BuyErez ChimovitsDirectorDirectorBuy1,940,000$35M
7 Aug 2026BuyChristopher ViehbacherDirectorDirectorBuy83,333$1.5M
7 Aug 2026BuyTravis MurdochCEO and PresidentCEO and PresidentBuy83,333$1.5M
7 Aug 2026BuyDavid Charles LubnerDirectorDirectorBuy55,555$1000K
7 Aug 2026BuyJames Paul RickeyChief Financial OfficerChief Financial OfficerBuy27,777$500K
7 Aug 2026BuyDavid I. MalekDirectorDirectorBuy4,166$75K
7 Aug 2026BuyMichele A. AndersonChief Development OfficerChief Development OfficerBuy1,111$20K

Not on file: no trades disclosed by members of Congress or officials since November 2023, no WARN layoff notices under its own name or a listed subsidiary's since November 2023, no open roles from its careers site yet, no earnings release figures from the last six months, no quarterly results in its SEC XBRL filings and no director or officer changes, WARN notices or large insider sales in the last two years. 13F holdings: Braveheart Bio listed after the last quarter (30 Jun 2026). The next 13F filings were due by 14 Nov 2026.